SYNOCURE® 867 BA 60 MY

Hydroxyl Functional Acrylic, 2.8% OH

ARKEMA COATING RESINS

Product Application details

SYNOCURE® 867 BA 60 MY is a hydroxy functional acrylic designed to crosslink at room temperature with polyisocyanates.

SYNOCURE® 867 BA 60 MY is especially recommended for coatings where outdoor durability and resistant properties are of prime importance.

Performance Benefits

- Excellent chemical and stain resistance
- Good durability
- Excellent adhesion
- Long pot life

Polymer Type

Solventborne Acrylic

Sales Specifications

Solid Content at 125°C, % (ISO 3251)	58 - 62
Viscosity at 25°C, mPa.s (ISO 3219)	3500 - 6000
Colour, Hazen Scale (ISO 6271)	70 max
Acid value, mg KOH/g (ISO 2114)	8 max

Other Characteristics¹

Volatile	Butyl acetate
Density / Specific Gravity at 25°C, g/ml (ISO 2811)	1.02
Hydroxyl Content, %	2.8
Hydroxyl Equivalent weight	600

Note: Acid value and/or Hydroxyl value quoted relative to solid resin

1 The data provided for these properties are typical values, intended only as guides, and should not be construed as sales specifications

RECOMMENDATIONS FOR USE

SYNOCURE® 867 BA 60 MY should be mixed with the selected polyisocyanate just prior to application. The mixing ratio is not critical, although it is preferable to use stoichiometric ratios to obtain optimum performance.

The reaction ratio is calculated from the respective equivalent weight or hydroxyl and isocyanate content of the reactants. The relationship is:

Hydroxyl equivalent weight = $\frac{17 \times 100}{\% \text{ OH}}$

Isocyanate equivalent weight = $\frac{42 \times 100}{\% \text{ NCO}}$

Formulation Guidelines

Using Desmodur[®] N 75 series (1) or Tolonate[™] HDB 75 MX (2), the recommended ratios would be:

	on solid resin	as supplied
SYNOCURE® 867 BA 60 MY	600	1000
Desmodur® N 75 series (1) or Tolonate™ HDB 75 MX (2)	191	255

When mixed with polyisocyanates in stoichiometric proportions, SYNOCURE® 867 BA 60 MY has a pot life in excess of 8 hours at temperatures from 15°C to 30°C. This usable period will be reduced in high temperature conditions or when catalysts are used.



The initial curing rate can be increased by the use of tin or zinc catalysts such as dibutyl tin dilaurate or zinc octoate. The levels used will depend on the specific requirements, but typical metal contents calculated on total solid resin are 0.001% tin and 0.0015% zinc.

Coatings prepared from SYNOCURE® 867 BA 60 MY and stoichiometric quantities of polyisocyanates will have sand dry times of approximately 15min and hard dry times of 1h.

SOLUBILITY

Solvents used in systems containing SYNOCURE® 867 BA 60 MY should be low water content grades and not contain chemical groups (such as hydroxyl) which will react with isocyanates and thereby inhibit the film forming reaction. Esters and ketones are true solvents for this type of system, usually combined with aromatic hydrocarbon diluents.

Notes: (1) Covestro, (2) Vencorex Chemicals

Product Safety

Please refer to the corresponding Safety Data Sheet.

Storage & Handling

SYNOCURE® 867 BA 60 MY should be stored indoors in the original, unopened and undamaged container, in a dry place at a temperature not exceeding 30°C. Exposure to direct sunlight should be avoided.

In the above mentioned storage conditions the shelf life of the resin will be 12 months

The statements, technical information and recommendations contained herein are believed to be accurate as of the date hereof. Since the conditions and methods of use of the product and of the information referred to herein are beyond our control, Arkema expressly disclaims any and all liability as to any results obtained or arising from any use of the product or reliance on such information; NO WARRANTY OF FITNESS FOR ANY PARTICULAR PURPOSE, WARRANTY OF MERCHANTABILITY OR ANY OTHER WARRANTY, EXPRESSED OR IMPLIED, IS MADE CONCERNING THE GOODS DESCRIBED OR THE INFORMATION PROVIDED HEREIN. The information provided herein relates only to the specific product designated and may not be applicable when such product is used in combination with other rarials or in any process. The user should thoroughly test any application before commercialization. Nothing contained herein constitutes a license to practice under any patent and it should not be construed as an inducement to infringe any patent and the user is advised to take appropriate steps to be sure that any proposed use of the product will not result in patent infringement. See SDS for Health & Safety Considerations.

Arkema has implemented a Medical Policy regarding the use of Arkema products in medical devices applications that are in contact with the body or circulating bodily fluids (http://www.arkema.com/en/social-responsibility/responsibile-product-management/medical-device-policy/index.html) Arkema has designated medical grades to be used for such medical device applications. Products that have not been designated as medical grades are not authorized by Arkema for use in medical device applications that are in contact with the body or circulating bodily fluids applications. Products that have not been designated as medical grades are not authorized by Arkema for use in medical device applications that are in contact with the body or circulating bodily fluids. In addition, Arkema strictly prohibits the use of any Arkema products in medical device applications that are in contact with bodily fluids or tissues for greater than 30 days. The Arkema trademarks and the Arkema name shall not be used in conjunction with customers' medical devices, including without limitation, permanent or temporary implantable devices, and customers shall not represent to anyone else, that Arkema allows, endorses or permits the use of Arkema products in such medical devices.

It is the sole responsibility of the manufacturer of the medical device to determine the suitability (including biocompatibility) of all raw materials, products and components, including any medical grade Arkema products, in order to ensure that the final end-use product is safe for its end use; performs or functions as intended; and complies with all applicable legal and regulatory requirements (FDA or other national drug agencies). It is the sole responsibility of the manufacturer of the medical device to conduct all necessary tests and inspections and to evaluate the medical device under actual end-use requirements and to adequately advise and warn purchasers, users, and/or learned intermediaries (such as physicians) of pertinent risks and fulfill any postmarket surveillance obligations. Any decision regarding the appropriateness of a particular Arkema material in a particular medical device should be based on the judgment of the manufacturer, seller, the competent authority, and the treating physician.

Arkema Coating Resins Malaysia Sdn Bhd



